Endothelial Caveolin-1 regulates the radiation response of epithelial prostate tumors

In vitro modeling of the prostate cancer microenvironment

(2014) Stuart J. Ellem et al.   ADVANCED DRUG DELIVERY REVIEWS

The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer

(2014) H B Ragnum et al.   BRITISH JOURNAL OF CANCER

Improved Functionality of the Vasculature during Conventionally Fractionated Radiation Therapy of Prostate Cancer

(2014) Vincent A. Potiron et al.   PLoS One

Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models

(2013) Salahaldin A. Tahir et al.   CANCER BIOLOGY & THERAPY

Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo

(2013) O. Dakhova et al.   CLINICAL CANCER RESEARCH

Combination of Vessel-Targeting Agents and Fractionated Radiation Therapy: The Role of the SDF-1/CXCR4 Pathway

(2013) Fang-Hsin Chen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Identification of prostate cancer risk categories according to surgical margins status, pathological stage and Gleason score

(2013) Riccardo Schiavina et al.   INTERNATIONAL JOURNAL OF UROLOGY

Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression

(2013) Gustavo Ayala et al.   JOURNAL OF PATHOLOGY

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

(2013) T Karantanos et al.   ONCOGENE

Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer

(2012) M. Milosevic et al.   CLINICAL CANCER RESEARCH

The reactive stroma microenvironment and prostate cancer progression

(2012) David A Barron et al.   ENDOCRINE-RELATED CANCER

Anti-caveolin-1 Antibodies As Anti-Prostate Cancer Therapeutics

(2012) Shu-Ru Kuo et al.   HYBRIDOMA

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer

(2012) Kathrine Røe et al.   Radiation Oncology

Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit

(2012) Paul G Corn   Cancer Management and Research

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease spread and epithelial Akt activation

(2011) Dolores Di Vizio et al.   CELL CYCLE

Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate

(2011) B Orr et al.   ONCOGENE

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients

(2010) Guillaume Ploussard et al.   BJU INTERNATIONAL

Angiogenesis inhibitors in the treatment of prostate cancer

(2010) Clara Hwang et al.   Journal of Hematology & Oncology

Overexpression of Caveolin-1 in Lymphoblastoid TK6 Cells Enhances Proliferation After Irradiation with Clinically Relevant Doses

(2010) David Barzan et al.   STRAHLENTHERAPIE UND ONKOLOGIE

An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers

(2009) Agnieszka K. Witkiewicz et al.   AMERICAN JOURNAL OF PATHOLOGY

Gene expression down-regulation in CD90+prostate tumor-associated stromal cells involves potential organ-specific genes

(2009) Laura E Pascal et al.   BMC CANCER

Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer

(2009) O. Dakhova et al.   CLINICAL CANCER RESEARCH

Radical prostatectomy for high-risk prostate cancer: Biochemical outcome

(2009) Naoki Kawamorita et al.   INTERNATIONAL JOURNAL OF UROLOGY

Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium

(2009) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of caveolin-1 in prostate cancer: clinical implications

(2009) T C Thompson et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells

(2009) Stephanie Hehlgans et al.   RADIOTHERAPY AND ONCOLOGY

Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer

(2009) Emma K Beardsley et al.   Current Opinion in Supportive and Palliative Care

Localized prostate cancer: can we better define who is at risk of unfavourable outcome?

(2008) Steven Joniau et al.   BJU INTERNATIONAL

Caveolin-1 in tumor progression: the good, the bad and the ugly

(2008) Jacky G. Goetz et al.   CANCER AND METASTASIS REVIEWS

Tumor Cell-Secreted Caveolin-1 Has Proangiogenic Activities in Prostate Cancer

(2008) S. A. Tahir et al.   CANCER RESEARCH

Combination of Vascular Endothelial Growth Factor Receptor/Platelet-Derived Growth Factor Receptor Inhibition Markedly Improves Radiation Tumor Therapy

(2008) C. Timke et al.   CLINICAL CANCER RESEARCH

Molecular Cancer Phenotype in Normal Prostate Tissue

(2008) Thorsten Schlomm et al.   EUROPEAN UROLOGY

Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study

(2008) Roy Vergis et al.   LANCET ONCOLOGY

MDR1Gene Transfer Using a Lentiviral SIN Vector Confers Radioprotection to Human CD34+Hematopoietic Progenitor Cells

(2008) Patrick Maier et al.   RADIATION RESEARCH